Page last updated: 2024-08-18

pyrroles and bortezomib

pyrroles has been researched along with bortezomib in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	23 (41.82)	29.6817
2010's	27 (49.09)	24.3611
2020's	5 (9.09)	2.80

Authors

Authors	Studies
Giles, FJ	1
Bailly, C; Lansiaux, A	1
von Mehren, M	1
Shiotsu, Y	1
Anderson, KC; Berkers, C; Catley, L; Chao, TH; Chauhan, D; Hideshima, T; Letai, A; Li, G; Mitsiades, C; Mitsiades, N; Neuteboom, ST; Nicholson, B; Ovaa, H; Palladino, MA; Podar, K; Richardson, P; Velankar, M; Yasui, H	1
Chandra, J; Keating, M; Krupnik, Y; McConkey, D; Palladino, M; Ruiz, S	1
Bernasconi, P; Calatroni, S; Crosetto, N; Dikic, I	1
Chao, TH; Cusack, JC; Liu, R; Neuteboom, ST; Niu, W; Palladino, MA; Palombella, VJ; Pien, C; Xia, L	1
Blank, JL; Bruzzese, FJ; Cao, Y; Daniels, JS; Dick, LR; Labutti, J; Mazzola, AM; Patil, AD; Reimer, CL; Rolfe, M; Solomon, MS; Stirling, M; Tian, Y; Tsu, CA; Weatherhead, GS; Williamson, MJ; Zhang, JX	1
Campo, E; Colomer, D; Pérez-Galán, P; Roué, G; Villamor, N	1
Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A	1
Acoca, S; Beauparlant, P; Bélec, L; Billot, X; Cluse, L; Goulet, D; Johnstone, RW; Marcellus, RC; Murthy Madiraju, SR; Nguyen, M; Purisima, E; Roulston, A; Serfass, L; Shore, GC; Viallet, J; Watson, M; Wiegmans, A	1
Anderson, KC; Azab, A; Azab, F; Burwick, N; Chauhan, D; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Palladino, MA; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP	1
Baritaki, S; Berenson, J; Bonavida, B; Daniels, TR; Jazirehi, AR; Palladino, M; Penichet, ML; Spandidos, DA; Suzuki, E; Umezawa, K	1
Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Nguyen, M; Pérez-Galán, P; Roué, G; Shore, GC; Villamor, N	1
Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L	1
Chandra, J; Keating, MJ; Miller, CP; Palladino, M; Rudra, S; Wierda, WG	1
Chan, W; Heymach, J; McConkey, DJ; Wilkinson, M; Zhu, K	1
Fuchs, O; Kuzelova, K; Marinov, I; Provaznikova, D; Spicka, I	1
Tsukamoto, S; Yokosawa, H	1
Schiff, D; van den Bent, MJ; Wen, PY	1
Orlowski, RZ; Shah, JJ	1
Baritaki, S; Berenson, J; Bonavida, B; Palladino, M; Yeung, K	1
Dunner, K; McConkey, DJ; Zhu, K	1
Abal, L; Casanova, JM; Dolcet, X; Egido, R; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Moreno, S; Puig, S; Santacana, M; Sorolla, A; Valls, J; Velasco, A; Vilella, R; Yeramian, A	1
Goldschmidt, H; Moehler, T	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M	1
Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A	1
Kale, AJ; Lechner, A; McGlinchey, RP; Moore, BS	1
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J	1
Baumann, P; Junghanns, C; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Strobl, S	1
Gallastegui, N; Groll, M	1
Bergadà, L; Dolcet, X; Llombart-Cussac, A; Martí, RM; Matias-Guiu, X; Sorolla, A; Valls, J; Yeramian, A	1
Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M	1
Abe, M; Fujii, S	1
Hu, Y; Wu, P; Zhang, J	1
Andriamanana, I; Duretz, B; Gana, I; Hulin, A	1
Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E	1
Anderl, JL; Assaraf, YG; Cloos, J; Jansen, G; Kale, AJ; Kaspers, GJ; Moore, BS; Niewerth, D; Riethoff, LF; van Meerloo, J; Zweegman, S	1
Chen, S; Dai, Y; Grant, S; Jones, R; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L	1
Chandra, J; Corrales-Medina, FF; Manton, CA; Orlowski, RZ	1
Angelucci, E; Annese, T; Catacchio, I; Dammacco, F; De Veirman, K; Derudas, D; Desantis, V; Di Marzo, L; Frassanito, MA; Fumarulo, R; Maffia, M; Menu, E; Nico, B; Racanelli, V; Ria, R; Ribatti, D; Ruggieri, S; Vacca, A; Vanderkerken, K; Vergara, D	1
Bailey, CP; Bouchier-Hayes, L; Chandra, J; Johnson, B; Manton, CA; Singh, M	1
Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J	1
Moreau, P; Rajkumar, SV	1
Bocchia, M; Brambilla, CZ; Candi, V; Gozzetti, A; Papini, G; Sirianni, S	1
Bullova, P; Cougnoux, A; Kopacek, J; Marzouca, G; Pacak, K	1
Grammatico, S; Petrucci, MT; Scalzulli, E; Vozella, F	1
Dai, L; Li, Y; Liu, S; Liu, X; Luo, X; Que, F; Xu, Y; Yu, L; Zhou, D; Zhu, Y	1
Li, J; Sherman, DJ	1
Anderson, KC; Cho, SF; Hsieh, PA; Kinneer, K; Li, Y; Lin, L; Liu, J; Munshi, N; Tai, YT; Wen, K; Xing, L; Yu, T	1
Ashelford, K; Corcoran, DB; Fegan, CD; Giles, PJ; Lewis, T; Miraz Rahman, K; Pepper, AGS; Pepper, C; Thurston, DE; Walsby, EJ	1
Mason, WP; Richardson, PG; Roth, P; Weller, M	1
Deng, K; Ding, C; Hong, B; Li, H; Lin, WC; Liu, XL; Lui, VWY; Lv, XT; Shi, WH; Yin, YP	1

Reviews

17 review(s) available for pyrroles and bortezomib

Article	Year
New drugs in acute myeloid leukemia. Current oncology reports, 2002, Volume: 4, Issue:5 Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides	2002
New therapeutic strategies for soft tissue sarcomas. Current treatment options in oncology, 2003, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin	2003
[Current screening for molecular target therapy of cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib	2003
Targeting ubiquitin in cancers. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:18 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Cycle; Genetic Therapy; Heat-Shock Proteins; Humans; Lactones; Neoplasms; Pyrazines; Pyrroles; Ubiquitin	2006
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovascular & hematological disorders drug targets, 2009, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lactones; Leukemia; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles	2009
Targeting the proteasome pathway. Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:5 Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins	2009
Neurological adverse effects caused by cytotoxic and targeted therapies. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration	2009
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 2009, Volume: 23, Issue:11 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lactones; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles	2009
Therapy of relapsed and refractory multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide	2011
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
Novel proteasome inhibitors to overcome bortezomib resistance. Journal of the National Cancer Institute, 2011, Jul-06, Volume: 103, Issue:13 Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination	2011
Clinical and marketed proteasome inhibitors for cancer treatment. Current medicinal chemistry, 2013, Volume: 20, Issue:20 Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine	2013
[Proteasome inhibitors in cancer therapy]. Postepy higieny i medycyny doswiadczalnej (Online), 2015, Dec-31, Volume: 69 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine	2015
Second Generation Proteasome Inhibitors in Multiple Myeloma. Anti-cancer agents in medicinal chemistry, 2017, Volume: 17, Issue:7 Topics: Animals; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Drug Discovery; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles; Threonine	2017
Proteasome inhibitors for the treatment of multiple myeloma. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:4 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Hematologic Diseases; Humans; Lactones; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Pyrroles	2018
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease. Molecules (Basel, Switzerland), 2020, Feb-05, Volume: 25, Issue:3 Topics: Antineoplastic Agents; Boron Compounds; Bortezomib; Glycine; Humans; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Proteostasis; Pyrroles	2020
Proteasome inhibition for the treatment of glioblastoma. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:10 Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Drug Development; Glioblastoma; Humans; Lactones; Proteasome Inhibitors; Pyrroles	2020

Trials

2 trial(s) available for pyrroles and bortezomib

Article	Year
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms	2013
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome	2014

Article

Year

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.

British journal of cancer, 2013, Mar-05, Volume: 108, Issue:4

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms

2013

A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.

Leukemia & lymphoma, 2014, Volume: 55, Issue:12

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome

2014

Other Studies

36 other study(ies) available for pyrroles and bortezomib

Article	Year
[Perspectives on the oncologist pharmacopoeia]. Bulletin du cancer, 2003, Volume: 90, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin	2003
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer cell, 2005, Volume: 8, Issue:5 Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Movement; Cell Proliferation; Drug Synergism; Genes, bcl-2; Humans; Lactones; Lymphocytes; Mice; Mitochondria; Multiple Myeloma; NF-kappa B; Plasmacytoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured	2005
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Molecular cancer therapeutics, 2006, Volume: 5, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles	2006
NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-15, Volume: 12, Issue:22 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Colonic Neoplasms; Drug Administration Routes; Drug Synergism; Female; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays	2006
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. Molecular cancer therapeutics, 2006, Volume: 5, Issue:12 Topics: Animals; Antineoplastic Agents; Binding, Competitive; Boronic Acids; Bortezomib; Drug Stability; Female; HeLa Cells; HT29 Cells; Humans; Lactones; Mice; Mice, Nude; Mice, SCID; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays	2006
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood, 2007, May-15, Volume: 109, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, Mantle-Cell; Molecular Mimicry; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Peptide Fragments; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured	2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, Feb-01, Volume: 111, Issue:3 Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays	2008
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-04, Volume: 104, Issue:49 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles	2007
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2008, May-01, Volume: 111, Issue:9 Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Death; Cell Movement; Cells, Cultured; Drug Delivery Systems; Drug Synergism; Humans; Lactones; Proteasome Inhibitors; Pyrazines; Pyrroles; Waldenstrom Macroglobulinemia	2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. Journal of immunology (Baltimore, Md. : 1950), 2008, May-01, Volume: 180, Issue:9 Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Lactones; Neoplasms; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Up-Regulation; YY1 Transcription Factor	2008
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, Volume: 22, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mitochondria; Phosphorylation; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Tumor Cells, Cultured	2008
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2008
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood, 2009, Apr-30, Volume: 113, Issue:18 Topics: Acetylation; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Drug Synergism; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Oxidative Stress; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Tumor Cells, Cultured; Vorinostat	2009
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer research, 2009, Mar-01, Volume: 69, Issue:5 Topics: Basic Helix-Loop-Helix Transcription Factors; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lactones; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Pyrazines; Pyrroles; RNA, Messenger; Vascular Endothelial Growth Factor A	2009
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer research, 2009, Nov-01, Volume: 69, Issue:21 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cisplatin; Humans; Lactones; Leupeptins; Male; Melanoma; Membrane Potential, Mitochondrial; NF-kappa B; Phosphatidylethanolamine Binding Protein; Prostatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-raf; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Transfection; Tumor Cells, Cultured	2009
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene, 2010, Jan-21, Volume: 29, Issue:3 Topics: Animals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Survival; Humans; Immunoblotting; Lactones; Lysosomes; Male; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Phagosomes; Prostatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Activating Enzymes	2010
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International journal of cancer, 2012, Feb-15, Volume: 130, Issue:4 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromones; Humans; Indoles; Melanoma; Morpholines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor Receptor-2	2012
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental hematology, 2011, Volume: 39, Issue:10 Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	2011
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A. ACS chemical biology, 2011, Nov-18, Volume: 6, Issue:11 Topics: Actinobacteria; Biological Products; Boronic Acids; Bortezomib; Drug Resistance, Bacterial; Humans; Lactones; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; Pyrroles; Substrate Specificity	2011
[Renal tolerance of targeted therapies]. Bulletin du cancer, 2012, Mar-01, Volume: 99, Issue:3 Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib	2012
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells. British journal of haematology, 2012, Volume: 156, Issue:5 Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Signal Transduction; Sulfonamides; Tumor Cells, Cultured	2012
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies. Methods in molecular biology (Clifton, N.J.), 2012, Volume: 832 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine	2012
Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. Molecular oncology, 2012, Volume: 6, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Endometrium; Female; Humans; Indoles; NF-kappa B; Pyrazines; Pyrroles; Sunitinib	2012
[Molecular targeting agents for multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide	2012
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, May-01, Volume: 926 Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles	2013
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib). Molecular pharmacology, 2014, Volume: 86, Issue:1 Topics: Actinobacteria; Boronic Acids; Bortezomib; Catalysis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia; Mutation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Up-Regulation	2014
Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Molecular and cellular biology, 2014, Sep-15, Volume: 34, Issue:18 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Cyclin T; Cyclin-Dependent Kinase 9; Cycloheximide; Flavonoids; Gene Expression Regulation; Heat-Shock Proteins; Humans; Indoles; Leupeptins; Membrane Proteins; Mice; Mice, Knockout; Mitochondrial Proteins; Piperidines; Protein Transport; Pyrazines; Pyrroles; RNA, Small Interfering; Sequestosome-1 Protein	2014
Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leukemia research, 2015, Volume: 39, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Hydroxamic Acids; Indoles; Lactones; Leukemia, Myeloid, Acute; Panobinostat; Proteasome Inhibitors; Pyrazines; Pyrroles; Tumor Cells, Cultured	2015
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia, 2016, Volume: 30, Issue:3 Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Autophagy; Bone Marrow Cells; Bortezomib; Drug Combinations; Drug Resistance, Neoplasm; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Microtubule-Associated Proteins; Middle Aged; Multiple Myeloma; Plasma Cells; Primary Cell Culture; Pyrazoles; Pyrroles; RNA-Binding Proteins; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases; Transforming Growth Factor beta; Xenograft Model Antitumor Assays	2016
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Scientific reports, 2016, Jan-25, Volume: 6 Topics: Animals; Apoptosis; Biomarkers, Tumor; Bortezomib; Caspases; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Lactones; Mice; Proliferating Cell Nuclear Antigen; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrroles	2016
Multiple myeloma--translation of trial results into reality. Lancet (London, England), 2016, Jul-09, Volume: 388, Issue:10040 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide	2016
Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. Endocrinology, 2017, 10-01, Volume: 158, Issue:10 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Lactones; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pheochromocytoma; Proteasome Inhibitors; Pyrroles	2017
[Bortezomib and obatoclax for dual blockade of protein degradation pathways show synergistic anti-tumor effect in human acute T lymphoblastic leukemia cells]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2019, Apr-30, Volume: 39, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Humans; Indoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles	2019
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia, 2020, Volume: 34, Issue:8 Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; B-Cell Maturation Antigen; Benzodiazepines; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; DNA Damage; Drug Synergism; Humans; Immunoconjugates; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrroles	2020
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers. Haematologica, 2021, 04-01, Volume: 106, Issue:4 Topics: Adenine; Animals; Apoptosis; Benzodiazepines; Bortezomib; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Piperidines; Pyrroles; Tumor Microenvironment	2021
Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer. Acta pharmacologica Sinica, 2021, Volume: 42, Issue:8 Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Drug Synergism; Forkhead Box Protein M1; HEK293 Cells; Humans; Indoles; Lung Neoplasms; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Oligopeptides; Proteasome Inhibitors; Pyrroles; Small Cell Lung Carcinoma; Up-Regulation; Xenograft Model Antitumor Assays	2021